Literature DB >> 34407962

European Society of Gynaecological Oncology guidelines for the peri-operative management of advanced ovarian cancer patients undergoing debulking surgery.

Christina Fotopoulou1, François Planchamp2, Tugce Aytulu3, Luis Chiva4, Alessandro Cina5, Önder Ergönül3, Anna Fagotti5,6, Dimitrios Haidopoulos7, Annette Hasenburg8, Cathy Hughes9, Pawel Knapp10, Philippe Morice11, Stephanie Schneider12, Jalid Sehouli13, Emmanouil Stamatakis14, Stephanie Suria15, Cagatay Taskiran16, Ralf Ulrich Trappe17, Jeremy Campbell18.   

Abstract

The European Society of Gynaecological Oncology (ESGO) developed and established for the first time in 2016, and updated in 2020, quality indicators for advanced ovarian cancer surgery to audit and improve clinical practice in Europe and beyond. As a sequela of the continuous effort to improve oncologic care in patients with ovarian cancer, ESGO issued in 2018 a consensus guidance jointly with the European Society of Medical Oncology addressing in a multidisciplinary fashion 20 selected key questions in the management of ovarian cancer, ranging from molecular pathology to palliation in primary and relapse disease. In order to complement the above achievements and consolidate the promoted systemic advances and surgical expertise with adequate peri-operative management, ESGO developed, as the next step, clinically relevant and evidence-based guidelines focusing on key aspects of peri-operative care and management of complications as part of its mission to improve the quality of care for women with advanced ovarian cancer and reduce iatrogenic morbidity. To do so, ESGO nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of ovarian cancer (18 experts across Europe). To ensure that the guidelines are evidence based, the literature published since 2015, identified from a systematic search, was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 117 independent international practitioners in cancer care delivery and patient representatives. © IGCS and ESGO 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ovarian cancer

Mesh:

Year:  2021        PMID: 34407962     DOI: 10.1136/ijgc-2021-002951

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  6 in total

Review 1.  Considerations for multimodal prehabilitation in women with gynaecological cancers: a scoping review using realist principles.

Authors:  Rhia Kaur Saggu; Phillip Barlow; John Butler; Sadaf Ghaem-Maghami; Cathy Hughes; Pernilla Lagergren; Alison H McGregor; Clare Shaw; Mary Wells
Journal:  BMC Womens Health       Date:  2022-07-19       Impact factor: 2.742

Review 2.  Paraaortic Lymphadenectomy in Gynecologic Oncology-Significance of Vessels Variations.

Authors:  Stoyan Kostov; Ilker Selçuk; Angel Yordanov; Yavor Kornovski; Hakan Yalçın; Stanislav Slavchev; Yonka Ivanova; Svetla Dineva; Deyan Dzhenkov; Rafał Watrowski
Journal:  J Clin Med       Date:  2022-02-11       Impact factor: 4.241

3.  Standardizing HIPEC and perioperative care for patients with ovarian cancer in the Netherlands using a Delphi-based consensus.

Authors:  Ruby M van Stein; Christianne A R Lok; Arend G J Aalbers; Ignace H J T de Hingh; Aletta P I Houwink; Herman J Stoevelaar; Gabe S Sonke; Willemien J van Driel
Journal:  Gynecol Oncol Rep       Date:  2022-02-26

Review 4.  Novel Ex Vivo Models of Epithelial Ovarian Cancer: The Future of Biomarker and Therapeutic Research.

Authors:  James Clark; Christina Fotopoulou; Paula Cunnea; Jonathan Krell
Journal:  Front Oncol       Date:  2022-03-25       Impact factor: 6.244

5.  Factors Predicting 30-Day Grade IIIa-V Clavien-Dindo Classification Complications and Delayed Chemotherapy Initiation after Cytoreductive Surgery for Advanced-Stage Ovarian Cancer: A Prospective Cohort Study.

Authors:  Malika Kengsakul; Gatske M Nieuwenhuyzen-de Boer; Suwasin Udomkarnjananun; Stephen J Kerr; Helena C van Doorn; Heleen J van Beekhuizen
Journal:  Cancers (Basel)       Date:  2022-08-29       Impact factor: 6.575

6.  Influence of anesthetic technique on survival after tumor debulking surgery of elderly patients with ovarian cancer: Results of a retrospective cohort study.

Authors:  Katharina Anic; Mona Wanda Schmidt; Annika Droste; Roxana Schwab; Marcus Schmidt; Slavomir Krajnak; Miriam Renz; Erik Kristoffer Hartmann; Roland Hardt; Annette Hasenburg; Marco Johannes Battista
Journal:  Oncol Lett       Date:  2022-08-26       Impact factor: 3.111

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.